Even after yesterday’s disappointing decline, the All Ordinaries index is up 20% since the start of the year.
Whilst this is an impressive gain, a number of shares on the index have outperformed it by a significant margin.
Here’s why these All Ords shares have more than tripled in value in 2019:
The AVITA Medical Ltd (ASX: AVH) share price has been the best performer on the index this year with a stunning 425% gain. Investors have been fighting to get hold of the global regenerative medicine company’s shares due to the potential of its RECELL System. The RECELL System is a regeneration platform which received U.S. FDA approval late last year as a Class III device for the treatment of acute thermal burns. The treatment area that the platform can handle is a massive 80x the donor area. This means that a skin sample the size of just a credit card can be used to treat a patient’s entire back. Management estimates that its U.S. market opportunity is worth US$5.7 billion per year. And judging by its share price rise, some investors appear to believe the technology could grab a decent slice of it.
The iSignthis Ltd (ASX: ISX) share price has zoomed a remarkable 381% higher in 2019. The neobank and global RegTech leader’s shares have been impressive performers this year thanks partly to the success of its Paydentity platform. Paydentity is the company’s trusted back office solution for regulated entities. It incorporates payment authentication with enhanced due diligence to remotely link a person’s verified identity to an electronic payment in order to satisfy anti-money laundering and counter-terrorism financing (AML/CTF) regulatory requirements. Combined with its wholesale neobank business and extensive card payment channel capability, some in the market appear to believe that iSignthis could be Australia’s answer to U.S. giant PayPal.
The Phoslock Environmental Technologies Ltd (ASX: PET) share price is up an enormous 261% since the start of the year. The environmental technologies company’s shares have been on fire this year thanks to a series of positive developments. One of these was the results of a trial application of its technology in a heavily polluted lake in South West China. According to the release, its trial resulted in a 75% reduction of phosphorus over the first four days of the application. The results also demonstrated to government authorities that Phoslock was simple to apply and the application had no effect on fish, plant life, or humans.
Missed these incredible gains? Then don't miss out on this hot stock which could be next in line to surge higher.
A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming. To the tune of an estimated $US22 billion.
Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.
Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.
AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.
Simply click below to learn more on how you can profit from the coming cannabis boom.
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends PayPal Holdings. The Motley Fool Australia has recommended PayPal Holdings. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.